BioCentury | Mar 5, 2012
Company News

Galen, Gilead sales and marketing update

...formulation of daunorubicin is approved in the U.S. to treat AIDS/HIV-associated Kaposi's sarcoma. Galen said Diatos S.A....
...DaunoXome under a 2006 deal, returned rights to the product to Gilead as part of Diatos'...
BioCentury | Apr 11, 2011
Clinical News

OncoGel: Development discontinued

...system. OncoGel has Orphan Drug designation in the U.S. and Europe to treat esophageal cancer. Diatos...
...has rights to the product outside North America and Korea. BTG plc (LSE:BGC), London, U.K. Diatos S.A....
BioCentury | Mar 21, 2011
Clinical News

OncoGel regulatory update

...U.S. and is in Phase IIb testing for the indication, with data expected next half. Diatos...
...has rights to the compound outside North America and Korea. BTG plc (LSE:BGC), London, U.K. Diatos S.A....
BioCentury | Feb 28, 2011
Strategy

Gilead's cancer encore

...Inc. (now part of Astellas Pharma Inc. ) in 2001 . DaunoXome was licensed to Diatos S.A....
...Mass. Bristol-Myers Squibb Co . (NYSE:BMY), New York, N.Y. Calistoga Pharmaceuticals Inc. , Seattle, Wash. Diatos S.A....
BioCentury | Oct 19, 2009
Company News

Cellectis, Diatos deal

...Cellectis purchased Diatos' Vectocell peptide-based intracellular delivery technology for an undisclosed sum. Cellectis' plans for the...
...undisclosed sum. Cellectis' plans for the technology were not disclosed. Cellectis S.A. (Euronext:ALCLS), Romainville, France Diatos S.A....
BioCentury | Jan 5, 2009
Company News

Diatos, Drais deal

...The prodrug of SN38 delivered using Vectocell peptide-based intracellular delivery technology has completed preclinical development. Diatos...
...is in Phase I testing to treat advanced solid tumors (see BioCentury, Sept. 22, 2008). Diatos S.A....
BioCentury | Dec 23, 2008
Company News

Drais in-licenses Diatos' DTS-108

...The prodrug of SN38 delivered using Vectocell peptide-based intracellular delivery technology has completed preclinical development. Diatos...
BioCentury | Oct 20, 2008
Clinical News

DaunoXome daunorubicin regulatory update

...for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Diatos'...
...exclusive rights to the liposomal anthracycline from Gilead in 2006 (see BioCentury, May 15, 2006). Diatos S.A....
BioCentury | Aug 11, 2008
Clinical News

DTS-201: Phase IIa started

...weeks in 22 patients. The company licensed European rights to DTS-201 from Medarex in 2003. Diatos S.A....
BioCentury | Aug 11, 2008
Clinical News

DTS-201: Phase II started

...weeks in 40 patients. The company licensed European rights to DTS-201 from Medarex in 2003. Diatos S.A....
Items per page:
1 - 10 of 45
BioCentury | Mar 5, 2012
Company News

Galen, Gilead sales and marketing update

...formulation of daunorubicin is approved in the U.S. to treat AIDS/HIV-associated Kaposi's sarcoma. Galen said Diatos S.A....
...DaunoXome under a 2006 deal, returned rights to the product to Gilead as part of Diatos'...
BioCentury | Apr 11, 2011
Clinical News

OncoGel: Development discontinued

...system. OncoGel has Orphan Drug designation in the U.S. and Europe to treat esophageal cancer. Diatos...
...has rights to the product outside North America and Korea. BTG plc (LSE:BGC), London, U.K. Diatos S.A....
BioCentury | Mar 21, 2011
Clinical News

OncoGel regulatory update

...U.S. and is in Phase IIb testing for the indication, with data expected next half. Diatos...
...has rights to the compound outside North America and Korea. BTG plc (LSE:BGC), London, U.K. Diatos S.A....
BioCentury | Feb 28, 2011
Strategy

Gilead's cancer encore

...Inc. (now part of Astellas Pharma Inc. ) in 2001 . DaunoXome was licensed to Diatos S.A....
...Mass. Bristol-Myers Squibb Co . (NYSE:BMY), New York, N.Y. Calistoga Pharmaceuticals Inc. , Seattle, Wash. Diatos S.A....
BioCentury | Oct 19, 2009
Company News

Cellectis, Diatos deal

...Cellectis purchased Diatos' Vectocell peptide-based intracellular delivery technology for an undisclosed sum. Cellectis' plans for the...
...undisclosed sum. Cellectis' plans for the technology were not disclosed. Cellectis S.A. (Euronext:ALCLS), Romainville, France Diatos S.A....
BioCentury | Jan 5, 2009
Company News

Diatos, Drais deal

...The prodrug of SN38 delivered using Vectocell peptide-based intracellular delivery technology has completed preclinical development. Diatos...
...is in Phase I testing to treat advanced solid tumors (see BioCentury, Sept. 22, 2008). Diatos S.A....
BioCentury | Dec 23, 2008
Company News

Drais in-licenses Diatos' DTS-108

...The prodrug of SN38 delivered using Vectocell peptide-based intracellular delivery technology has completed preclinical development. Diatos...
BioCentury | Oct 20, 2008
Clinical News

DaunoXome daunorubicin regulatory update

...for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Diatos'...
...exclusive rights to the liposomal anthracycline from Gilead in 2006 (see BioCentury, May 15, 2006). Diatos S.A....
BioCentury | Aug 11, 2008
Clinical News

DTS-201: Phase IIa started

...weeks in 22 patients. The company licensed European rights to DTS-201 from Medarex in 2003. Diatos S.A....
BioCentury | Aug 11, 2008
Clinical News

DTS-201: Phase II started

...weeks in 40 patients. The company licensed European rights to DTS-201 from Medarex in 2003. Diatos S.A....
Items per page:
1 - 10 of 45